New Triple-Drug attack on tough liver cancer
NCT ID NCT06789757
Summary
This study is testing if adding an oral drug called memantine to two standard cancer drugs helps control advanced liver cancer better. It will involve about 19 adults with newly diagnosed, inoperable liver cancer. Participants will receive the three-drug combination in 21-day cycles for six months while researchers track how their cancer responds and how they feel.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Health Care Service
RECRUITINGFalls Church, Virginia, 22042, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Inova Schar Cancer Institute - Fair Oaks
RECRUITINGFairfax, Virginia, 22033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.